Search
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalin the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. … It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[A199122] Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways … Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have
Categories: MATE 2-K Inhibitors, MATE 1 InhibitorsPaltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalhormone (GH) and decreases the production of growth-promoting insulin-like growth factor 1 (IGF-1). … Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsPotassium carbonate
go.drugbank.com/drugs/DB13977ApprovedIt can be made as the product of potassium hydroxide's absorbent reaction with carbon dioxide. It presents a large capacity to absorb moisture. … Potassium carbonate (K2CO3) is a white salt, soluble in water (insoluble in ethanol) which forms a strongly alkaline solution.
Mixtures: Vit C W Calc-mag and Potass Powder, Buffered Vitamin C Powder With Ca Mg and KProducts: Food-S, Face-body-SRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. … [A190516] The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: Tiacumicin BLevorphanol
go.drugbank.com/drugs/DB00854ApprovedA narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.
Categories: Heterocyclic Compounds with 4 or More RingsAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). … It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsGuanfacine
go.drugbank.com/drugs/DB01018ApprovedInvestigationalGuanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesProducts: ARİSLOW ER 1 MG UZATILMIŞ SALIMLI TABLET, 7 TABLET, ARİSLOW ER 3 MG UZATILMIŞ SALIMLI TABLET, 7 TABLETRibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalAdditionally, including ribavirin in the regimen can increase the risk of anemia. … In HCV genotye 1/2/3/4/5/6 patients, ribavirin can be used in combination therapy involving [DB09102] and [DB08934], Eplusa ([DB08934], [DB11613]), Harvoni ([DB08934], [DB09027]), [DB06290] and [DB08934
Categories: Treatments for Hepatitis CSynonyms: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide